Technology Bundle ID
TAB-2295

An In-Vitro Cell System Useful For Identification of RORgamma Antagonists

Applications
Research Materials
Linked ID
E-253-2010-0
Lead Inventors
Anton Jetten (NIEHS)
Co-Inventors
Yukimasa Takeda (NIEHS)
Development Status
  • Early-stage
  • Pre-clinical
  • In vitro data available
ICs
NIEHS
The retinoid-related orphan receptors alpha, beta and gamma (RORalpha, beta and gamma , also referred to as NR1F1, 2 and 3, respectively) comprise a distinct subfamily of nuclear receptors. Study of ROR-deficient mice has implicated RORs in the regulation of a number of biological processes and revealed potential roles for these proteins in several pathologies. NIH investigators have developed an in-vitro system using CHO cells stably expressing a TET-On expression vector regulating RORgamma and a RORE-Luciferase reporter. This system allows inducible expression of RORgamma upon addition of doxycycline. Upon its induction RORgamma binds to the RORE in the luciferase reporter plasmid and induces luciferase. This system can be used to identify RORgamma antagonists. This system has been tested successfully in 1536-well plate high throughput analysis.
Commercial Applications
  • Identification of therapeutic compounds to treat asthma, inflammation, and various autoimmune diseases such as osteoarthritis, multiple sclerosis.
Competitive Advantages
  • Novel and unique system to screen and identify chemical and drugs for their RORgamma antagonistic activity.

Request More Info

Licensing Contact: